KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Equity Income (2016 - 2019)

Historic Equity Income for CRISPR Therapeutics AG (CRSP) over the last 4 years, with Q3 2019 value amounting to -$3.4 million.

  • CRISPR Therapeutics AG's Equity Income fell 23893.28% to -$3.4 million in Q3 2019 from the same period last year, while for Dec 2019 it was -$5.5 million, marking a year-over-year decrease of 2788.3%. This contributed to the annual value of -$5.5 million for FY2019, which is 2788.3% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Equity Income stood at -$3.4 million for Q3 2019, which was down 23893.28% from -$1.0 million recorded in Q2 2019.
  • CRISPR Therapeutics AG's 5-year Equity Income high stood at -$359000.0 for Q3 2017, and its period low was -$35.8 million during Q4 2016.
  • Over the past 4 years, CRISPR Therapeutics AG's median Equity Income value was -$1.0 million (recorded in 2018), while the average stood at -$3.7 million.
  • Its Equity Income has fluctuated over the past 5 years, first skyrocketed by 9873.63% in 2017, then plummeted by 23893.28% in 2019.
  • Over the past 4 years, CRISPR Therapeutics AG's Equity Income (Quarter) stood at -$35.8 million in 2016, then skyrocketed by 98.74% to -$453000.0 in 2017, then tumbled by 124.94% to -$1.0 million in 2018, then plummeted by 236.6% to -$3.4 million in 2019.
  • Its Equity Income was -$3.4 million in Q3 2019, compared to -$1.0 million in Q2 2019 and -$1.0 million in Q1 2019.